Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Triple therapy for Helicobacter pylori eradication is more effective than long‐term maintenance antisecretory treatment in the prevention of recurrence of duodenal ulcer: a prospective long‐term follow‐up study

View through CrossRef
Background: The effectiveness of Helicobacter pylori eradication treatment and long term acid suppression maintenance in the natural course of duodenal ulcer has not been directly compared.Aim: To compare in a prospective randomized study the effectiveness of H. pylori eradication on the prevention of recurrence of duodenal ulcer with long‐term maintenance acid suppression therapy.Methods: One hundred and fourteen duodenal ulcer patients were randomized to the treatment over a 12‐month period. Fifty‐seven of them received triple therapy consisting of 1 g sucralfate q.d.s. for 28 days, 300 mg metronidazole q.d.s. for 14 days and 250 mg clarithromycin q.d.s. for 14 days. Another 57 received 20 mg omeprazole q.d.s. for 12 months. An upper endoscopy was performed before treatment, at 6 weeks, and 2, 6 and 12 months after the first endoscopy. Side‐effects were self‐recorded and clinical follow‐ups were arranged for up to 4.25 years.Results: The ulcer healing rate was 90.2% (95% confidence interval (95% CI): 79–97%) in the omeprazole group at 6 weeks as compared to 83.3% (95% CI: 70–93%) in the triple therapy group (P = 0.38). There was a higher success rate of pain control in the omeprazole group. Side‐effects were more frequently reported and compliance was poorer in the triple therapy group during the first 4 weeks. During follow‐up, more relapses were seen in the omeprazole group (9.8%, 95% CI: 3–21%) than the triple therapy group (4.2%, 95% CI: 1–13%) at 1 year (P = 0.44). All relapses were due to the persistence of H. pylori infection. At the 1 year follow‐up, none of the patients who were H. pylori negative had an endoscopic relapse compared to 7 out of 56 patients who remained H. pylori positive (12.5%, 95% CI: 5–24%, P = 0.018). After a mean follow‐up of 4.07 years, none of those who remained H. pylori negative had an ulcer relapse while the 11 out of 41 who remained H. pylori positive had an ulcer relapse (26.8%, 95% CI 14–43, P = 0.0005).Conclusions: Both regimens were highly effective in healing ulcers. The eradication of H. pylori infection was associated with more side‐effects and poor compliance but was more effective than the maintenance therapy in reducing the recurrence of duodenal ulcers. For the prevention of ulcer recurrence, testing of H. pylori status after triple therapy is more important than maintenance therapy.
Title: Triple therapy for Helicobacter pylori eradication is more effective than long‐term maintenance antisecretory treatment in the prevention of recurrence of duodenal ulcer: a prospective long‐term follow‐up study
Description:
Background: The effectiveness of Helicobacter pylori eradication treatment and long term acid suppression maintenance in the natural course of duodenal ulcer has not been directly compared.
Aim: To compare in a prospective randomized study the effectiveness of H.
pylori eradication on the prevention of recurrence of duodenal ulcer with long‐term maintenance acid suppression therapy.
Methods: One hundred and fourteen duodenal ulcer patients were randomized to the treatment over a 12‐month period.
Fifty‐seven of them received triple therapy consisting of 1 g sucralfate q.
d.
s.
for 28 days, 300 mg metronidazole q.
d.
s.
for 14 days and 250 mg clarithromycin q.
d.
s.
for 14 days.
Another 57 received 20 mg omeprazole q.
d.
s.
for 12 months.
An upper endoscopy was performed before treatment, at 6 weeks, and 2, 6 and 12 months after the first endoscopy.
Side‐effects were self‐recorded and clinical follow‐ups were arranged for up to 4.
25 years.
Results: The ulcer healing rate was 90.
2% (95% confidence interval (95% CI): 79–97%) in the omeprazole group at 6 weeks as compared to 83.
3% (95% CI: 70–93%) in the triple therapy group (P = 0.
38).
There was a higher success rate of pain control in the omeprazole group.
Side‐effects were more frequently reported and compliance was poorer in the triple therapy group during the first 4 weeks.
During follow‐up, more relapses were seen in the omeprazole group (9.
8%, 95% CI: 3–21%) than the triple therapy group (4.
2%, 95% CI: 1–13%) at 1 year (P = 0.
44).
All relapses were due to the persistence of H.
pylori infection.
At the 1 year follow‐up, none of the patients who were H.
pylori negative had an endoscopic relapse compared to 7 out of 56 patients who remained H.
pylori positive (12.
5%, 95% CI: 5–24%, P = 0.
018).
After a mean follow‐up of 4.
07 years, none of those who remained H.
pylori negative had an ulcer relapse while the 11 out of 41 who remained H.
pylori positive had an ulcer relapse (26.
8%, 95% CI 14–43, P = 0.
0005).
Conclusions: Both regimens were highly effective in healing ulcers.
The eradication of H.
pylori infection was associated with more side‐effects and poor compliance but was more effective than the maintenance therapy in reducing the recurrence of duodenal ulcers.
For the prevention of ulcer recurrence, testing of H.
pylori status after triple therapy is more important than maintenance therapy.

Related Results

Evaluation of H. pylori - Eradication Triple Therapy in Iraqi Peptic Ulcer Patients according to ABO Phenotypes: a New Study
Evaluation of H. pylori - Eradication Triple Therapy in Iraqi Peptic Ulcer Patients according to ABO Phenotypes: a New Study
Infection with H. pylori is an up growing  public health problem that affects approximately 50% of people in industrialized nations, and up to 80% in developing countries. Helicoba...
Different regimens for eradication of Helicobacter pylori infection in children: a randomized controlled trial
Different regimens for eradication of Helicobacter pylori infection in children: a randomized controlled trial
Abstract Eradication of Helicobacter pylori (H. pylori) infection in children is challenging due to increased antibiotic resistance and decreased effectiveness of the cur...
Anti-Saccharomyces cerevisiae antibodies (ASCA) in peptic ulcer disease with Helicobacter pylori
Anti-Saccharomyces cerevisiae antibodies (ASCA) in peptic ulcer disease with Helicobacter pylori
Anti-Saccharomyces cerevisiae antibodies (ASCA) is related to the pathogenesis of Crohn’s disease as digestive tract inflammation. But the relationship between ASCA and peptic ulce...
Is the Only Good Helicobacter a Dead Helicobacter?
Is the Only Good Helicobacter a Dead Helicobacter?
Background.Vast numbers of therapeutic studies of various drug regimens used for the cure of H. pylori infection have been published. However, many of these studies have been uncon...
Jinghua Weikang capsule for helicobacter pylori eradication: A systematic review and meta-analysis with trial sequential analysis
Jinghua Weikang capsule for helicobacter pylori eradication: A systematic review and meta-analysis with trial sequential analysis
Background:Helicobacter pylori (H. pylori) infection is one of the most common chronic bacterial infections worldwide. The resistance of H. pylori to antibiotics may increase the r...

Back to Top